A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

C

CTTQ

Status and phase

Enrolling
Phase 2
Phase 1

Conditions

Advanced Malignancies
Metastatic Breast Cancer
Recurrent Breast Cancer

Treatments

Drug: TQB3616 capsule
Drug: Eribulin mesylate injection
Drug: gemcitabine hydrochloride for injection
Drug: Fulvestrant injection
Drug: Vinorelbine tartrate injection
Drug: TQB2930 for injection
Drug: Paclitaxel for injection (albumin-bound)
Drug: Capecitabine tablets

Study type

Interventional

Funder types

Industry

Identifiers

NCT06202261
TQB2930-Ib/II-01

Details and patient eligibility

About

This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).

Enrollment

154 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0~1; The expected survival is over 3 months.

  • Phase Ib

    1. Advanced malignancies confirmed by cytology / histopathology, priority given to subjects with HER2 expression or amplification;
    2. Subjects with malignant tumors who have failed standard treatment or lack effective treatment;
    3. Confirmed presence of at least one evaluable lesion according to RECIST 1.1 criteria
  • Phase II

    1. Hormone receptor (HR)-negative, HER2-positive breast cancer confirmed by cytology / histopathology, with evidence of local recurrence or distant metastasis, unsuitable for surgery or radiotherapy for curative purposes:
    2. Have not received systemic antitumor therapy for metastatic stage; Systemic use of endocrine therapy is permitted, but not exceed 2 lines;
    3. at least one measurable lesion that meets the RECIST 1.1 criteria.
  • Major organs are functioning normally.

  • Female subjects of reproductive age should agree to use contraceptive methods during the study period and until 6 months after the end of the study; Negative serum pregnancy / urine pregnancy test within 7 days prior to study enrollment and must be non-lactating subjects; Male subjects should agree to use contraception during the study and until six months after the end of the study.

Exclusion criteria

  • Have occured other malignant tumors within 3 years prior to first dose.
  • Unalleviated toxicity above Common Terminology Criteria for Adverse Events (CTCAE) grade 1 due to any prior treatment;
  • Received major surgical treatment, open biopsy, or significant traumatic injury within 28 days prior to the first dose;
  • Long-term unhealed wounds or fractures;
  • Arterial/venous thrombosis events occurred within 6 months before the first dose;
  • Have a history of psychotropic drug abuse and can't get rid of it or have mental disorders;
  • Subject with any severe and/or uncontrolled disease;
  • Subjects who have been treated with other antitumor agents such as chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first dose, within 5 half-lives of the drug;
  • Have used traditional chinese medicine with anti-tumor indications approved by National Medical Products Administration (NMPA) within 2 weeks before the first dose;
  • Severe bone injury due to bone metastasis;
  • Subjects with untreated active brain metastases or meningeal metastases or cancerous meningitis;
  • In the course of previous HER2-targeted therapy, Left Ventricular Ejection Fractions (LVEF) decreased to <50% or absolute LVEF decreased >15%;
  • Cumulative doses of anthracyclines exceeded doxorubicin or doxorubicin liposomes >360 mg/m2;
  • Uncontrolled hypercalcemia or symptomatic hypercalcemia requires continued bisphosphonate therapy
  • Patients with severe hypersensitivity after the use of monoclonal antibodies;
  • Has participated in other antitumor clinical trials within 4 weeks prior to the first dose.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

154 participants in 4 patient groups

TQB2930 for injection
Experimental group
Description:
TQB2930 for injection,10 mg/kg, quaque week (QW), 21 day as a treatment cycle; TQB2930 for injection, 20 mg/kg, quaque 2 weeks (Q2W), 28 day as a treatment cycle; TQB2930 for injection,30 mg/kg, quaque 3 weeks (Q3W), 21 day as a treatment cycle.
Treatment:
Drug: TQB2930 for injection
TQB2930 for injection 30mg/kg + Paclitaxel for injection (albumin-bound)
Experimental group
Description:
TQB2930 for injection 30mg/kg combined with paclitaxel (albumin-bound) for injection, 21 days for one treatment cycle
Treatment:
Drug: Paclitaxel for injection (albumin-bound)
Drug: TQB2930 for injection
TQB2930 for injection+TQB3616 capsule for injection + fulvestrant injection
Experimental group
Description:
TQB2930 for injection 20mg/kg combined with TQB3616 capsule 120mg or 150mg or 180mg, and fulvestrant injection. Q2W, 28 days a cycle.
Treatment:
Drug: TQB2930 for injection
Drug: Fulvestrant injection
Drug: TQB3616 capsule
TQB2930 for injection + chemotherapy
Experimental group
Description:
TQB2930 for injection 30mg/kg combined with capecitabine tablets or vinorelbine tartrate injection or eribulin mesylate injection or gemcitabine hydrochloride for injection, 21 days a cycle.
Treatment:
Drug: Capecitabine tablets
Drug: Vinorelbine tartrate injection
Drug: TQB2930 for injection
Drug: gemcitabine hydrochloride for injection
Drug: Eribulin mesylate injection

Trial contacts and locations

2

Loading...

Central trial contact

Qingyuan Zhang, Doctor; Xiaohua Zeng, Doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems